Cidara Therapeutics Inc (NASDAQ: CDTX) on Monday, plunged -24.54% from the previous trading day, before settling in for the closing price of $0.68. Within the past 52 weeks, CDTX’s price has moved between $0.59 and $1.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -1248.08%. With a float of $81.59 million, this company’s outstanding shares have now reached $90.62 million.
Cidara Therapeutics Inc (CDTX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cidara Therapeutics Inc is 9.96%, while institutional ownership is 29.71%. The most recent insider transaction that took place on Mar 11 ’24, was worth 14,085. In this transaction CHIEF SCIENTIFIC OFFICER of this company sold 21,029 shares at a rate of $0.67, taking the stock ownership to the 258,681 shares. Before that another transaction happened on Mar 11 ’24, when Company’s Chief Medical Officer sold 20,662 for $0.67, making the entire transaction worth $13,839. This insider now owns 347,095 shares in total.
Cidara Therapeutics Inc (CDTX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -1248.08% per share during the next fiscal year.
Cidara Therapeutics Inc (NASDAQ: CDTX) Trading Performance Indicators
Cidara Therapeutics Inc (CDTX) is currently performing well based on its current performance indicators. A quick ratio of 1.55 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.38, a number that is poised to hit -0.86 in the next quarter and is forecasted to reach -2.44 in one year’s time.
Technical Analysis of Cidara Therapeutics Inc (CDTX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.24 million. That was better than the volume of 0.7 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 3.13%. Additionally, its Average True Range was 0.11.
During the past 100 days, Cidara Therapeutics Inc’s (CDTX) raw stochastic average was set at 1.90%, which indicates a significant increase from 1.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 145.33% in the past 14 days, which was higher than the 85.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7691, while its 200-day Moving Average is $0.8346. However, in the short run, Cidara Therapeutics Inc’s stock first resistance to watch stands at $0.6079. Second resistance stands at $0.7018. The third major resistance level sits at $0.7557. If the price goes on to break the first support level at $0.4601, it is likely to go to the next support level at $0.4062. The third support level lies at $0.3123 if the price breaches the second support level.
Cidara Therapeutics Inc (NASDAQ: CDTX) Key Stats
Market capitalization of the company is 46.57 million based on 90,619K outstanding shares. Right now, sales total 64,290 K and income totals -29,800 K. The company made 12,720 K in profit during its latest quarter, and -8,170 K in sales during its previous quarter.
